

What is claimed is:

1. A method for the treatment of a disease resulting from platelet activation, the method comprising administering a biologically-effective amount of a nucleic acid ligand to a  $\beta_3$  integrin.

5

2. A method for treating deep vein thrombosis comprising administering a biologically-effective amount of a nucleic acid ligand to a  $\beta_3$  integrin.

10 3. A pharmaceutical composition for the treatment of deep vein thrombosis comprising a nucleic acid ligand to a  $\beta_3$  integrin and a pharmaceutically acceptable excipient.

4. A method for detecting a deep vein thrombosis in an individual, the method comprising:

15

(a) providing a nucleic acid ligand to a  $\beta_3$  integrin, said nucleic acid ligand conjugated to a radioactive label;

(b) administering said nucleic acid ligand to said individual;

(c) detecting the site of said thrombosis by analyzing the localization of said nucleic acid ligand using a radioimaging technique.

20

5. An anti-clotting composition for use in acute coronary syndromes and percutaneous coronary intervention, the composition comprising a nucleic acid ligand to a  $\beta_3$  integrin and a pharmaceutically-acceptable excipient.

25

6. A method for the treatment of a disease in which  $\alpha_v\beta_3$  activation is a contributing pathogenic factor, the method comprising administering a biologically-effective dose of a nucleic acid ligand to  $\alpha_v\beta_3$  and a pharmaceutically acceptable excipient.

30

7. The method of claim 6 wherein said disease is selected from the group consisting of cancer, diabetic retinopathy, retinopathy of prematurity, macular

degeneration, endometriosis, psoriasis, rheumatoid arthritis, stroke, osteoporosis, and restenosis.